Open an account

NovaBridge Biosciences

NBP · NASDAQ

$1.43+$0.125 (+9.62%)TodayMarket closed ·
Prev close $1.30

About NBP

NovaBridge Biosciences operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company is headquartered in Rockville, Maryland and currently employs 30 full-time employees. The company went IPO on 2020-01-17. The firm combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is completing a large, randomized, dose-ranging Phase 2 study for wet AMD.

Employees
30
Headquarters
Rockville, Maryland
Listed
Jan 17, 2020
Sector
Health Care
Industry
Biotechnology
Website
novabridge.com

NBP key statistics

Market cap
150.80M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
708.15K
Volume
658.00K
Open price
$1.30
High today
$1.46
Low today
$1.30
52 Week high
$5.97
52 Week low
$1.26

NovaBridge Biosciences (NBP) at a glance

As of Oct 20, 2026, NovaBridge Biosciences (NBP) shares are priced at $1.43, giving the company a market cap of 150.80M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.30 and $1.46. The current price is 9.6% above the day's low and 2.4% below its high.

Volume so far is 658.00K shares, in line with the average of 708.15K shares a day.

Over the past year NovaBridge Biosciences has ranged from $1.26 to $5.97, and now sits 4% of the way up that range.

NovaBridge Biosciences met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q4 FY25 it reported -$0.29 per share against an estimate of -$0.053.

The average analyst price target is $8.93, 526.3% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $8.93
Low
$8.08
Now
$1.43
High
$9.45

NBP earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 40.5% on average.

  1. Q1 FY24: reported -$0.21 per share against an estimate of -$0.2218
  2. Q2 FY24: reported -$0.46 per share against an estimate of -$1.31
  3. Q3 FY24: reported -$0.25 per share against an estimate of -$0.2344
  4. Q4 FY24: reported -$0.08 per share against an estimate of -$0.0572
  5. Q1 FY25: reported -$0.03 per share against an estimate of -$0.0657
  6. Q2 FY25: reported -$0.066 per share against an estimate of -$0.0404
  7. Q3 FY25: reported -$0.03 per share against an estimate of -$0.048
  8. Q4 FY25: reported -$0.29 per share against an estimate of -$0.053

NBP news

  • Press releasePRNewswire

    Hiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater China

  • Press releaseGlobe Newswire

    NovaBridge Biosciences to Participate in September Investor Conferences

  • Press releaseGlobe Newswire

    NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference

  • Press releaseGlobe Newswire

    NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

  • Press releaseGlobe Newswire

    NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study

  • Press releaseGlobe Newswire

    NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026

  • Press releaseGlobe Newswire

    NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference

  • Press releasePRNewswire

    Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape

Similar companies

Companies in the same industry as NovaBridge Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.